Anavar 10 mg 50 Tabs Saxon Pharma USA
$99.00
Product Short Description
Anavar 10 mg 50 Tabs Saxon Pharma USA delivers oxandrolone (C19H30O3), the 17α-ethyl-Δ¹-DHT derivative exhibiting mild anabolic activity (~322-630:24 ratio) with minimal androgenicity, at exact 10 mg strength identical to historical Oxandrin tablets. Domestic U.S. production eliminates customs exposure serving DEA Schedule III compliant institutional channels through verified performance networks.
Product Overview
Saxon Pharma USA’s Anavar 10 mg presents oxandrolone, featuring unique 2-oxa lactone ring conferring exceptional oral bioavailability (~9-10 hour half-life) and low hepatotoxicity profile among 17α-alkylated steroids, in small oval white scored tablets precisely replicating Oxandrin (BTG) morphology for institutional catalog integration across DEA-registered platforms. The 50-tablet HDPE bottle configuration supports CIII-compliant inventory reconciliation under 21 CFR 1304.22 requiring detailed Schedule III tracking for institutional handlers.
U.S.-domiciled GMP manufacturing maintains molecular specifications (MW 306.44) matching FDA reference standards while distinguishing legitimate Schedule III pedigree from underground powder conversions exhibiting characteristic under-dosing. This authentic presentation serves institutional buyers requiring Form 222 triplicate documentation across U.S. jurisdictions, eliminating international sourcing risks.
Saxon Anavar positions exclusively within verified DEA Schedule III ecosystems targeting licensed institutional clientele under 21 CFR 1301.13 registrant requirements.
Brand & Manufacturer Information
Saxon Pharma USA manufactures DEA Schedule III controlled substances through domestic GMP facilities serving institutional performance networks requiring DEA registrant verification. Anavar 10 mg anchors Saxon’s mild oral anabolic catalog alongside Primo/Winstrol maintaining dosage standardization while authenticating supply chain legitimacy versus powder-pressed alternatives rejected by institutional handlers.
Domestic warehousing supports Form 222 platforms eliminating customs risk while serialized batch documentation verifies 10 mg potency distinguishing Saxon from non-pharmaceutical origins.
Active Compound Information
Contains oxandrolone (17β-hydroxy-17α-methyl-2-oxa-5α-androstan-3-one), exhibiting 2-oxa lactone modification conferring 6x testosterone anabolic potency with 0.3x androgenic activity characteristic of DHT-derived 17α-alkyl steroids enabling oral bioavailability without 17α-methyl hepatotoxicity. DEA Schedule III classification reflects lipid profile alteration potential and mild virilization risk profile supporting extended administration.
10 mg strength matches historical Oxandrin 10 mg (NDC 54487-454-30) reference while 50-tablet count supports institutional packaging. Molecular formula C19H30O3; WADA S1.1a prohibited globally.
Product Specifications
| Specification | Details |
|---|---|
| Product Name | Anavar 10 mg 50 Tabs Saxon Pharma USA |
| Active Compound | Oxandrolone (C19H30O3) |
| Strength | 10 mg per oval scored tablet |
| Quantity | 50 tablets per HDPE bottle |
| Form | Oral scored tablets (Oxandrin equivalent) |
| Category | DEA Schedule III controlled substance |
| Appearance | White, oval, single-scored |
| Molecular Weight | 306.44 g/mol |
| Half-Life | ~9-10 hours |
| Label Elements | “10 mg”, CIII warnings, serialized lot |
Quality Control & Testing Standards
10 mg oxandrolone mandates USP <621> potency assay (HPLC 95-105%), USP <711> dissolution, USP <905> uniformity, and lactone ring verification confirming pharmaceutical-grade specifications matching Oxandrin monographs. Saxon batch records document C19H30O3 identity distinguishing GMP production from underground conversions.
50-tablet CIII configuration incorporates USP <671> HDPE barriers with child-resistant closure satisfying 21 CFR 310.310(a). Stability maintains ICH Q1A(R2) 36-month shelf-life.
Intended Use & Market Positioning
Anavar 10 mg serves DEA-registered CIII institutional researchers managing mild-potency Schedule III anabolic inventories through encrypted fulfillment requiring Form 222 accountability. Serves verified institutional clientele exclusively.
Zero protocols, cycles, or outcomes represented maintaining commercial CIII positioning.
Legal & Regulatory Disclaimer
Oxandrolone constitutes DEA Schedule III under 21 USC §812; non-medical handling violates Controlled Substances Act (5 years/$250,000 penalties). Institutional buyers assume Form 222/DEA licensing liability; no medical claims provided.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.
Reviews
There are no reviews yet.